BACKGROUND AND OBJECTIVE: to describe the development or progression of subfoveal fibrosis after anti-vascular endothelial growth factor (VEGF) therapy in the absence of significant subfoveal hemorrhage in neovascular age-related macular degeneration. PATIENTS AND METHODS: retrospective case series. RESULTS: seven eyes of seven patients with neovascular age-related macular degeneration developed subfoveal fibrosis after anti-VEGF therapy in the absence of significant subfoveal hemorrhage. Five of seven patients experienced vision loss of 0.3 logarithm of the minimum angle of resolution units or greater. CONCLUSION: subfoveal fibrosis may develop or progress in neovascular age-related macular degeneration despite the absence of significant subfoveal hemorrhage and treatment with anti-VEGF. Development of anti-fibrotic therapeutics may be beneficial in reducing the incidence of subretinal fibrosis.
BACKGROUND AND OBJECTIVE: to describe the development or progression of subfoveal fibrosis after anti-vascular endothelial growth factor (VEGF) therapy in the absence of significant subfoveal hemorrhage in neovascular age-related macular degeneration. PATIENTS AND METHODS: retrospective case series. RESULTS: seven eyes of seven patients with neovascular age-related macular degeneration developed subfoveal fibrosis after anti-VEGF therapy in the absence of significant subfoveal hemorrhage. Five of seven patients experienced vision loss of 0.3 logarithm of the minimum angle of resolution units or greater. CONCLUSION: subfoveal fibrosis may develop or progress in neovascular age-related macular degeneration despite the absence of significant subfoveal hemorrhage and treatment with anti-VEGF. Development of anti-fibrotic therapeutics may be beneficial in reducing the incidence of subretinal fibrosis.
Authors: Ebenezer Daniel; Cynthia A Toth; Juan E Grunwald; Glenn J Jaffe; Daniel F Martin; Stuart L Fine; Jiayan Huang; Gui-shuang Ying; Stephanie A Hagstrom; Katrina Winter; Maureen G Maguire Journal: Ophthalmology Date: 2013-12-04 Impact factor: 12.079
Authors: T Nakama; S Yoshida; K Ishikawa; Y Kobayashi; Y Zhou; S Nakao; Y Sassa; Y Oshima; K Takao; A Shimahara; K Yoshikawa; T Hamasaki; T Ohgi; H Hayashi; A Matsuda; A Kudo; M Nozaki; Y Ogura; M Kuroda; T Ishibashi Journal: Gene Ther Date: 2014-12-11 Impact factor: 5.250
Authors: Michael M Altaweel; Ebenezer Daniel; Daniel F Martin; Robert A Mittra; Juan E Grunwald; Michael M Lai; Alexander Melamud; Lawrence S Morse; Jiayan Huang; Frederick L Ferris; Stuart L Fine; Maureen G Maguire Journal: Ophthalmology Date: 2014-10-11 Impact factor: 12.079